Garetosmab
3 papers1 finding
- 1 lab
- Human trial2
- Animals1
Outcomes
1Lean mass loss
downin humans1
1 study
Lean mass loss
downin humans1
Garetosmab decreases lean mass loss in humans (-2.5% (LLM) and -1.8% (non-LLM) vs -7.1% and -5.9%).
“there was significantly less LM loss in the trevo 200mg, 400mg, and triplet groups vs sema alone”
Human trialwith or without low lean mass at baseline400mg trevogrumab + 10 mg/kg garetosmab + 2.4mg semaglutide26 weeksn = 599
ADA Scientific Sessions 2026 abstract7 Jun 2026
Latest
2 in 12 monthsADA Scientific Sessions 2026 Abstract
Lean Mass Effects of Anti-GDF8 (Trevogrumab) ± Anti-Activin A (Garetosmab) in People Living with Obesity Treated with Semaglutide with or without Low Lean Mass at Baseline
Randomised trial in 599 peopleObesity
ADA Scientific Sessions 2026 Abstract
Population-Normed Z-scores for Body Composition Enhance Sensitivity and Effect Size: Analysis of a Phase 2 RCT Testing Anti-GDF8 and Anti-Activin A on Top of Semaglutide (COURAGE)
Randomised trial in 599 peopleSemaglutide
ADA Scientific Sessions 2025 Abstract
Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model
Experiments in ratsInterventions